{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:57:25Z","timestamp":1790686645517,"version":"4.1.0"},"reference-count":37,"publisher":"Academy of Managed Care Pharmacy","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.18553\/jmcp.2026.32.10.1296","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:07:12Z","timestamp":1790683632000},"page":"1296-1310","source":"Crossref","is-referenced-by-count":0,"title":["Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed\/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis"],"prefix":"10.18553","volume":"32","author":[{"given":"Bijal D.","family":"Shah","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibuzo","family":"Iloabuchi","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Harrigan","sequence":"additional","affiliation":[{"name":"RainCity Analytics, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markqayne","family":"Ray","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Santaolalla Revenga","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cobley","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Nissen","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[{"name":"RainCity Analytics, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24797"},{"issue":"4","key":"r3","first-page":"524","author":"Fitzmaurice C","year":"2017","journal-title":"JAMA Oncol"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450"},{"key":"r6","unstructured":"American Cancer Society. Key Statistics for Acute Lymphocytic Leukemia (ALL). https:\/\/www.cancer.org\/cancer\/types\/acute-lymphocytic-leukemia\/about\/key-statistics.html"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216883"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19081"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-551937"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01797"},{"key":"r15","unstructured":"Oluwole O, Armin G, Cassaday R, et al. Five-year survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukaemia (R\/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3. Poster presented at: EHA 2025; June 12-15, 2025; Milan, Italy."},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02532-7"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01379-0"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30493-0"},{"key":"r19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015478"},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-04851-0"},{"key":"r21","doi-asserted-by":"crossref","unstructured":"Hoover A, Reimche P, Watson D, et\u00a0al. Healthcare cost and utilization for chimeric antigen receptor (CAR) T-cell therapy in the treatment of pediatric acute lymphoblastic leukemia: a commercial insurance claims database analysis.\n                      Cancer Rep (Hoboken\n                      ). 2024;7(2):e1980. doi:10.1002\/cnr2.1980","DOI":"10.1002\/cnr2.1980"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.020"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030164"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2215888"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.547"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013962"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.03.015"},{"issue":"3","key":"r29","first-page":"262","volume":"31","author":"Kilgore KM","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.017"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174681"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17673"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0647"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2438631"},{"key":"r35","unstructured":"FDA. Core Patient-Reported Outcomes in Cancer Clinical Trials. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"}],"container-title":["Journal of Managed Care &amp; Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:08:05Z","timestamp":1790683685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.10.1296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.18553\/jmcp.2026.32.10.1296"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.10.1296","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}